{"id":11447,"date":"2026-05-27T10:00:00","date_gmt":"2026-05-27T08:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=74be7c60ba08e91d66a503feb16fe23b"},"modified":"2026-05-27T10:00:00","modified_gmt":"2026-05-27T08:00:00","slug":"median-technologies-launches-a-capital-increase-of-e40-million-with-potential-upsize-to-e50-million-to-support-the-deployment-of-eyonis-lcs-in-the-u-s-and-europe-and-advance-new-clinical-indi","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=11447","title":{"rendered":"Median Technologies Launches a Capital Increase of \u20ac40 million, with Potential Upsize to \u20ac50 million, to Support the Deployment of eyonis\u00ae LCS in the U.S. and Europe and Advance New Clinical Indications for Its Proprietary eyonis\u00ae&#8230;"},"content":{"rendered":"<ul class=\"bwlistdisc\">\n<li>\nShare capital increase without shareholders\u2019 preferential subscription rights, to be carried out by way of an issue of ordinary shares in the framework of a public offering, for an amount of approximately 40 million euros.<\/li>\n<li>\nA share capital increase without shareholders\u2019 preferential subscription rights reserved for the Guarantors (as defined below) for a maximum amount of 10 million euros, should all the ordinary shares issued in the framework of the public offering be fully subscribed;<\/li>\n<li>\nFirm subscription and backstop commitments for a total amount of 30 million euros, including 20 million euros under the subscription commitments, representing total commitments equal to 75% of the public offering;<\/li>\n<li>\nSubscription price: 5.00 euros per ordinary share; and<\/li>\n<li>\nThe net proceeds of the share capital increase will be allocated to the commercial launch of eyonis<sup>\u00ae<\/sup> LCS in the United States and Europe, and to the financing of the extension of the eyonis<sup>\u00ae<\/sup> medical device software suite for the early diagnosis of cancers through imaging.<\/li>\n<\/ul><p>SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News:<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260526575567\/en\/2815622\/5\/Logo_Median_%281%29.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260526575567\/en\/2815622\/22\/Logo_Median_%281%29.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260526575567\/en\/2815622\/5\/Logo_Median_%281%29.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260526575567\/en\/2815622\/21\/Logo_Median_%281%29.jpg\" \/><\/a><p class=\"bwalignc\">\n<b>Median Technologies Launches a Capital Increase of \u20ac40 million, with Potential Upsize to \u20ac50 million, to Support the Deployment of eyonis<sup>\u00ae<\/sup> LCS in the U.S. and Europe and Advance New Clinical Indications for Its Proprietary eyonis<sup>\u00ae<\/sup> Pan-Cancer Early Diagnostics Suite<\/b><\/p><p class=\"bwalignc\">\nNOT FOR DIRECT OR INDIRECT DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN<\/p><p>\nMedian Technologies (<i><strong>FR0011049824, ALMDT<\/strong>, PEA-PME scheme eligible, \u201cMedian\u201d or the \u201cCompany\u201d<\/i>), developer of eyonis<sup>\u00ae<\/sup>, a suite of artificial intelligence (AI) powered Software as Medical Devices (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today announces the launch of a share capital increase without of shareholders\u2019 preferential subscription rights by way of an issue of ordinary shares (the \u201c<b>New Shares<\/b>\u201d), for a maximum amount of approximately 50 million euros. The New Shares will be offered in the framework of (i) a public offering in France and a global placement to certain qualified investors for a global amount of approximately 40 million euros (together, the \u201c<b>Global Offering<\/b>\u201d) and (ii) an offering reserved to the Guarantors for a maximum amount of 10 million euros (the \u201c<b>Reserved Offering<\/b>\u201d and, together with the Global Offering, the \u201c<b>Offering<\/b>\u201d).<\/p><p>\nThe Company has already received subscription backstop commitments for an amount of \u20ac30 million.<\/p><p>\nSubscription period of the public offering will close on June 3, 2026 at 5:00 pm CEST.<\/p><p>\n<b>Fredrik Brag, CEO and Founder of Median Technologies commented: <\/b><i>\u201cThe defining truth in oncology is simple: outcomes are determined by the stage at which cancer is diagnosed. When cancer is diagnosed early, it is often curable. When diagnosed late, it becomes complex, costly, and frequently fatal. Despite major advances in treatment, most healthcare systems remain structurally focused on late-stage disease. A structural shift is now possible: advances in AI applied to medical imaging make large-scale early cancer diagnosis operational.<\/i><\/p><p>\n<i>Median Technologies operates at the convergence of three powerful forces: AI, medical imaging, and early cancer diagnosis. Our proprietary eyonis<sup>\u00ae<\/sup> platform is designed to develop multiple AI-based SaMD for the early detection and diagnosis of cancers within existing clinical workflows and to act as a force multiplier for healthcare systems.<\/i><\/p><p>\n<i>Our first indication, eyonis<sup>\u00ae<\/sup> LCS for lung cancer screening, achieved FDA 510(k) clearance in February 2026. eyonis<sup>\u00ae<\/sup> LCS is positioned as a clinically validated and deployable SaMD combining early identification with clinically actionable diagnostic decision support. This places us at the forefront of a shift from treating cancer reactively to driving early-stage curative diagnosis.<\/i><\/p><p>\n<i>This financing is intended to fund the U.S. commercial rollout of eyonis<sup>\u00ae<\/sup> LCS in the lung cancer screening indication, and allows us to launch our device in Europe after CE mark achievement. It will also enable the Company to continue and accelerate the development of additional AI-based Software as Medical Devices within the eyonis<sup>\u00ae<\/sup> portfolio, targeting new cancer indications. It will provide the Company with a cash runway until the first half-year 2028, when we expect to have demonstrated meaningful commercial traction in lung cancer. We welcome Lion Point Capital\u2019s and the Guarantors\u2019 continued and reinforced commitment, which provides all our existing shareholders the opportunity to participate in this important next phase, while ensuring the Company has the resources required to deliver on its strategic priorities.\u201d<\/i><\/p><p>\n<b>INTENDED USE OF THE TRANSACTION\u2019S NET PROCEEDS<\/b><\/p><p>\nThe net proceeds from the transaction will be used:<\/p><ul class=\"bwlistdisc\">\n<li>\nTo accelerate commercialization of eyonis<sup>\u00ae<\/sup> LCS in the U.S. and launch in target European countries after CE marking achievement,<\/li>\n<li>\nTo develop eyonis<sup>\u00ae<\/sup> for incremental cancer indications,<\/li>\n<li>\nFor Company\u2019s working capital and general corporate purposes.<\/li>\n<\/ul><p>\nThe transaction will extend Company\u2019s cash runway until first half-year 2028, in case of full subscription.<\/p><p>\nIt should be noted that 12 million warrants issued in July 2025 are currently outstanding, with an expiry date in January 2028, at an exercise price of \u20ac2.39 per share (remaining exercise value of \u20ac44.3 million). In case of full exercise of the 2025 warrants, the cash runway of the Company would be extended to mid-2029.<\/p><p>\n<b>EYONIS<sup>\u00ae<\/sup> LCS: TRANSFORMING LUNG CANCER SCREENING AT SCALE<\/b><\/p><p>\neyonis<sup>\u00ae<\/sup> LCS is Median Technologies\u2019 AI-powered SaMD built to improve lung cancer screening by combining detection and characterization of parenchymal pulmonary nodules from low-dose CT scans (LDCT) in one integrated radiology workflow. eyonis<sup>\u00ae<\/sup> LCS is designed to help clinicians identify cancer earlier\u2014when lung cancer is more likely to be treatable, while reducing diagnostic uncertainty that can drive unnecessary follow-up procedures. With demonstrated performance of 93.3% sensitivity, 92.4% specificity and 99.9% negative predictive value (NPV) (manufacturer values), eyonis<sup>\u00ae<\/sup> LCS supports confident clinical decision-making. These metrics are operationally decisive: high sensitivity supports early cancer identification, high specificity reduces unnecessary follow-up, very high NPV gives healthcare systems confidence in managing large screening populations efficiently.<\/p><p>\n<b>Commercial deployment of eyonis<sup>\u00ae<\/sup> LCS in the United States<\/b><\/p><p>\nIn February 2026, Median Technologies received FDA 510(k) clearance for eyonis<sup>\u00ae<\/sup> LCS, providing market authorization and enabling commercialization of the first AI tech-based detection and diagnosis SaMD for lung cancer screening across the United States.<\/p><p>\n<span class=\"bwuline\">The U.S. Lung Cancer Screening Market<\/span><\/p><p>\nLung cancer screening in the United States represents a large, well-structured and rapidly expanding market, addressing approximately 14.5 million eligible individuals nationwide. This market benefits from a clear and predictable reimbursement framework supported by the existing NT-APC pathway, enabling reimbursement for quantitative CT tissue characterization procedures performed alongside low-dose CT screening. Current reimbursement for these AI-based analyses is typically around $650 per procedure.<\/p><p>\nBased on these fundamentals, the annual total addressable market (TAM) for lung cancer screening is estimated at over $9 billion in the United States alone, driven by increasing adoption of low-dose CT screening programs and strong public health support for early cancer detection.<\/p><p>\neyonis<sup>\u00ae<\/sup> LCS is uniquely positioned to capture a significant share of this high-growth market by creating value at three levels:<\/p><ul class=\"bwlistdisc\">\n<li>\nClinical: earlier diagnosis, higher survival, more curative intervention.<\/li>\n<li>\nOperational: scalable screening, reduced radiology burden, improved workflow efficiency.<\/li>\n<li>\nEconomic: fewer late-stage treatments, fewer unnecessary procedures, lower system-wide cost.<\/li>\n<\/ul><p>\n<span class=\"bwuline\">Key milestones achieved to date<\/span><\/p><p>\nMedian Technologies has entered a decisive execution phase for the U.S. commercial deployment of eyonis<sup>\u00ae<\/sup> LCS, supported by strong strategic, organizational, and operational foundations. Key milestones achieved to date include:<\/p><ul class=\"bwlistdisc\">\n<li>\nStrategic distribution partnership: the signing of a non-exclusive agreement with Tempus AI, enabling integration of eyonis<sup>\u00ae<\/sup> LCS into clinical workflows via the Tempus Pixel platform and providing access to a broad network of healthcare providers.<\/li>\n<li>\nStrengthened U.S. leadership: the appointment of Oran Muduroglu as President of Median eyonis Inc., bringing extensive experience in scaling imaging and clinical workflow platforms and leading U.S. commercial execution.<\/li>\n<li>\nDeployment of a scalable go-to-market model: implementation of a multi-channel strategy combining direct enterprise sales, non-exclusive distribution partnerships, and integration into established clinical workflows.<\/li>\n<li>\nTargeted market segmentation: prioritization of high-potential segments, including Independent Diagnostic Testing Facilities (IDTFs) and the Veterans Affairs (VA) healthcare system.<\/li>\n<li>\nBuild-out of U.S. infrastructure: continued expansion of commercial, technological and clinical support capabilities, alongside engagement with leading United States healthcare institutions.<\/li>\n<\/ul><p>\n<span class=\"bwuline\">Upcoming catalysts<\/span><\/p><p>\nLooking ahead, several key catalysts are expected to accelerate commercial rollout and market penetration across the U.S.:<\/p><ul class=\"bwlistdisc\">\n<li>\nExpansion of the distribution network: execution of additional non-exclusive distribution agreements with leading imaging, cloud, and diagnostics partners to further scale market access in the United States.<\/li>\n<li>\nFocused deployment across priority segments: targeted rollout within IDTFs and the VA healthcare system to support both rapid initial adoption and large-scale, repeatable deployment.<\/li>\n<li>\nLeveraging KOL partnerships: engagement with leading clinical experts to drive thought leadership, support clinical validation, and accelerate adoption within lung cancer screening programs.<\/li>\n<li>\nDevelopment of health economics and outcomes research (HEOR): initiation of health-economic studies to demonstrate clinical and economic value, supporting broader and more sustainable long-term insurance coverage.<\/li>\n<li>\nProgressive site activation: first U.S. clinical sites expected to become operational in Q3 2026.<\/li>\n<li>\nInitial revenue generation: first revenues anticipated by year-end 2026.<\/li>\n<li>\nScaled commercial execution: continued expansion of the multi-channel model to support nationwide deployment and sustained market penetration.<\/li>\n<\/ul><p>\n<b>eyonis<sup>\u00ae<\/sup> LCS in Europe<\/b><\/p><p>\nThe Company expects a decision on eyonis<sup>\u00ae<\/sup> LCS CE marking in the coming weeks, paving the way for broad adoption and expanded access to potentially millions of patients across Europe.<\/p><p>\n<span class=\"bwuline\">Lung Cancer Screening in Europe<\/span><\/p><p>\nLung cancer screening programs across Europe are gaining momentum. While only a limited number of countries have established national programs\u2014such as England, Poland and Croatia\u2014Europe is entering an acceleration phase, illustrated by the launch of Germany\u2019s nationwide screening program in April 2026.<\/p><p>\nAt the same time, major countries including France, are advancing large-scale pilot initiatives designed to assess the feasibility of organized lung cancer screening in real-world settings. In France, the national IMPULSION study has been launched as a large-scale pilot program to evaluate the feasibility of implementing organized lung cancer screening using low-dose CT in a real-world setting, targeting approximately 20,000 high-risk individuals and combining screening with smoking cessation support.<\/p><p>\nItaly also stands out as one of the most advanced European countries in lung cancer screening, with a nationwide network-based approach (RISP) and multiple large-scale pilot programs already underway, providing a real-world foundation for the future expansion of organized screening.<\/p><p>\nAcross Europe, tens of millions of individuals are estimated to fall within high-risk categories potentially eligible for lung cancer screening, representing a substantial and largely untapped addressable market for early detection solutions.<\/p><p>\nThe key growth drivers for lung cancer screening in Europe are the transition from pilot programs to national deployment, increasing pressure on radiology capacity, and the progressive integration of standardized, AI-enabled workflows, which will create a strong foundation for scalable, technology-driven solutions such as eyonis<sup>\u00ae<\/sup> LCS.<\/p><p>\n<span class=\"bwuline\">Strategy for commercial launch and roll-out<\/span><\/p><p>\nMedian\u2019s go-to-market strategy for eyonis<sup>\u00ae<\/sup> LCS in Europe will be based on a balanced combination of direct and indirect sales channels, enabling both strong engagement with key stakeholders and broad geographic coverage. The Company will prioritize direct sales in strategic markets and leading screening centers to establish clinical partnerships, generate reference sites and demonstrate real-world value. In parallel, Median will leverage indirect channels\u2014including its non-exclusive distribution agreement with Tempus, which also covers Europe\u2014to accelerate deployment and expand access across healthcare networks.<\/p><p>\nIn addition, Median will actively engage with payers and healthcare authorities at nation level including France, to support the integration of eyonis<sup>\u00ae<\/sup> LCS into screening pathways, building on dedicated health-economic studies. As reimbursement models evolve across Europe, particularly in the context of organized screening programs, the Company expects AI-enabled solutions such as eyonis<sup>\u00ae<\/sup> LCS to become increasingly integrated into standard care pathways.<\/p><p>\nThe commercial rollout of eyonis<sup>\u00ae<\/sup> LCS will initially focus on European markets that are at the forefront of lung cancer screening deployment, including Poland, Germany, Italy and France. These markets are characterized either by existing lung cancer screening programs or by the progressive transition from pilot initiatives to structured, large-scale screening programs, creating immediate demand for scalable and operationally efficient solutions. By prioritizing early-adopter countries, Median aims to accelerate market penetration and establish a strong commercial footprint in the most advanced healthcare systems.<\/p><p>\nUltimately, Median\u2019s ambition is to position eyonis<sup>\u00ae<\/sup> LCS as a core technological building block of lung cancer screening infrastructure. By combining detection and diagnosis capabilities within a single AI-driven solution, and by addressing key challenges related to capacity, standardization and efficiency, eyonis<sup>\u00ae<\/sup> LCS is designed to support the long-term expansion and sustainability of lung cancer screening programs across Europe.<\/p><p>\n<b>Portfolio expansion<\/b><\/p><p>\n<span class=\"bwuline\">eyonis<sup>\u00ae<\/sup>: Median\u2019s proprietary pan-cancer suite of early diagnostic tests<\/span><\/p><p>\nGlobally, approximately 20 million new cancer cases and nearly 10 million deaths are recorded annually. By 2050, annual cancer incidence is expected to exceed 35 million cases. The total economic burden of cancer is projected to exceed $25 trillion over the coming decades. Healthcare systems currently allocate enormous resources to advanced-stage disease, where outcomes are poorest and costs are highest. Early diagnosis reverses this logic by shifting intervention into the window where cure is still possible.<\/p><p>\nLung cancer is only the first indication. As eyonis<sup>\u00ae<\/sup> expands into additional high-burden cancers \u2014 including liver, pancreatic, colorectal, and prostate cancers \u2014 the long-term opportunity becomes a multi-billion-dollar, pan-cancer indication platform.<\/p><p>\nBeyond lung cancer screening, Median Technologies will continue to advance the development of its broader eyonis<sup>\u00ae<\/sup> portfolio, including programs targeting incidental pulmonary nodules (IPN) and hepatocellular carcinoma (HCC), which address significant unmet needs in oncology. Both eyonis<sup>\u00ae<\/sup> IPN and eyonis<sup>\u00ae<\/sup> HCC programs are strategically aligned with Median\u2019s long-term ambition to expand eyonis<sup>\u00ae<\/sup> into a comprehensive portfolio of AI-based SaMD, reinforcing the Company\u2019s positioning in AI-enabled early cancer diagnosis and supporting future growth opportunities beyond its initial lung cancer screening indication.<\/p><p>\n<span class=\"bwuline\">eyonis<\/span><span class=\"bwuline\"><sup>\u00ae<\/sup> IPN<\/span><\/p><p>\nIn the area of IPN, Median is positioning its solutions to improve the identification, characterization and clinical management of lung nodules detected incidentally on routine imaging, a segment widely recognized as a major opportunity for earlier diagnosis given the high prevalence of such findings.<\/p><p>\nAs of today, a substantial proportion of lung cancers are detected outside of organized screening programs. Studies indicate that up to two-thirds of resectable lung cancers in asymptomatic patients may be identified incidentally.<\/p><p>\nThe combination of eyonis<sup>\u00ae<\/sup> LCS and eyonis<sup>\u00ae<\/sup> IPN within a single integrated portfolio has the potential to significantly transform early lung cancer detection by enabling both population-based screening of at-risk individuals and opportunistic detection in patients undergoing routine CT imaging for other indications. By addressing both screening-eligible populations and the large proportion of patients who fall outside current eligibility criteria but still undergo imaging, this dual approach expands the reach of early detection and diagnosis and represents a key opportunity to improve outcomes at scale.<\/p><p>\n<span class=\"bwuline\">eyonis<\/span><span class=\"bwuline\"><sup>\u00ae<\/sup> HCC<\/span><\/p><p>\nThe eyonis<sup>\u00ae<\/sup> HCC program focuses on advancing AI-driven imaging biomarkers and diagnostic capabilities to support earlier detection and improved treatment decision-making in HCC, a disease with high mortality and historically low early diagnosis rates.<\/p><p>\n<b>NATURE AND LEGAL BASIS OF THE OFFERING<\/b><\/p><p>\nAt its meeting held on May 27, 2026, the Company\u2019s Board of Directors decided to launch:<\/p><ul class=\"bwlistdisc\">\n<li>\na share capital increase without shareholders\u2019 preferential subscription rights by way of a public offering, pursuant to the 3rd resolution adopted by the combined general meeting of the Company\u2019s shareholders held on October 31, 2025 (the \u201c<b>General Meeting<\/b>\u201d); and<\/li>\n<li>\na share capital increase without shareholders\u2019 preferential subscription rights reserved for a category of persons, for the benefit of Guarantors, pursuant to the 5th resolution adopted by the General Meeting, in accordance with Article L.225-138 of the French Commercial Code.<\/li>\n<\/ul><p>\nThe Global Offering will comprise:<\/p><ul class=\"bwlistdisc\">\n<li>\nA public offering in France, mainly aimed at retail investors (the \u201c<b>Public Offering<\/b>\u201d); and<\/li>\n<li>\nAn international offering to qualified investors in certain countries, including (a) in the United States of America, by way of a private placement by the Company to a limited number of \u201cqualified institutional buyers\u201d as defined in Rule 144A under the U.S. Securities Act of 1933, as amended (the \u201cSecurities Act\u201d), in reliance on an exemption from the registration requirements of Section 4(a)(2) of the Securities Act, and (b) outside the United States in offshore transactions in accordance with Regulation S under the Securities Act (the \u201c<b>Global Placement<\/b>\u201d).<\/li>\n<\/ul><p>\nThe distribution of the New Shares to the public in France will be carried out in accordance with the applicable provisions of the Euronext market rules.<\/p><p>\nTD Cowen &amp; Stifel are Joint Global Coordinators and Joint Placement Agents for the Offering (together, the \u201c<b>Banks<\/b>\u201d).<\/p><p>\n<b>Subscription and backstop commitments<\/b><\/p><p>\nThe Company entered into, on 26 May 2026, with Lion Point Capital, a shareholder of the Company whose founder and manager, Mr Didric Cedholm, sits on the Company\u2019s Board of Directors, an undertaking entitled \u201c<i>Backstop Commitment Agreement<\/i>\u201d, pursuant to which Lion Point Capital undertakes to subscribe for and underwrite a share capital increase of the Company for an amount of up to EUR 30,000,000, until 15 September 2026, irrespective of the level of subscription by other investors, with Lion Point Capital being entitled to involve, in whole or in part, \u201c<i>Co Backstop Parties<\/i>\u201d as co-subscribers and co-commitment parties, without being released from its own obligations towards the Company (the \u201c<b>Backstop Agreement<\/b>\u201d).<\/p><p>\nLion Point Capital has notified the Company that Katarina Martinson AB, Venture S.a.r.l, and Nordica Life (Bermuda) Ltd have undertaken, in accordance with the Backstop Agreement, to subscribe for and underwrite any share capital increase of the Company until September 15, 2026 (together, the \u201c<b>Guarantors<\/b>\u201d).<\/p><p>\nAccordingly, the Company benefits from the following subscription undertakings (the \u201c<b>Subscription Commitments<\/b>\u201d):<\/p><table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwsinglebottom bwpadl0 bwwidth31\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwwidth12 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n<b>New Shares<\/b><\/p><\/td><td class=\"bwsinglebottom bwwidth2 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwwidth24 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n<b>Subscribed amount (\u20ac)<\/b><\/p><\/td><td class=\"bwsinglebottom bwwidth2 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwwidth27 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n<b>% of the Public Offering<\/b><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth31\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nKatarina Martinson AB<\/p><\/td><td class=\"bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n2,666,667<\/p><\/td><td class=\"bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth24\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n13,333,333<\/p><\/td><td class=\"bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth27 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n33.3 %<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth31\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nVenture S.a.r.l<\/p><\/td><td class=\"bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n933,333<\/p><\/td><td class=\"bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth24\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n4,666,667<\/p><\/td><td class=\"bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth27 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n11.7 %<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth31\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nNordica Life (Bermuda) Ltd<\/p><\/td><td class=\"bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n400,000<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwpadb3 bwwidth24\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n2,000,000<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwpadb3 bwwidth27 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n5.0 %<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth31\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>TOTAL<\/b><\/p><\/td><td class=\"bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>4,000,000<\/b><\/p><\/td><td class=\"bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth24\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>20,000,000<\/b><\/p><\/td><td class=\"bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth27 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n<b>50 %<\/b><\/p><\/td><\/tr>\n<\/table><p>\nThe Company has not received any other subscription commitments from its shareholders or from the members of its management or administrative bodies.<\/p><p>\nFurthermore, the Company also benefits from the following guarantee undertakings (the \u201c<b>Backstop Commitments<\/b>\u201d):<\/p><table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwsinglebottom bwpadl0 bwwidth31\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwwidth12 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n<b>New Shares<\/b><\/p><\/td><td class=\"bwsinglebottom bwwidth2 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwwidth24 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n<b>Subscribed amount (\u20ac)<\/b><\/p><\/td><td class=\"bwsinglebottom bwwidth2 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwwidth27 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n<b>% of the Public Offering<\/b><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth31\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nKatarina Martinson AB<\/p><\/td><td class=\"bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n1,333,333<\/p><\/td><td class=\"bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth24\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n6,666,667<\/p><\/td><td class=\"bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth27 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n16.7 %<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth31\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nVenture S.a.r.l<\/p><\/td><td class=\"bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n466,667<\/p><\/td><td class=\"bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth24\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n2,333,333<\/p><\/td><td class=\"bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth27 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n5.8 %<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth31\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nNordica Life (Bermuda) Ltd<\/p><\/td><td class=\"bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n200,000<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwpadb3 bwwidth24\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n1,000,000<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwpadb3 bwwidth27 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n2.5 %<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth31\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>TOTAL<\/b><\/p><\/td><td class=\"bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>2,000,000<\/b><\/p><\/td><td class=\"bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth24\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>10,000,000<\/b><\/p><\/td><td class=\"bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth27 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n<b>25 %<\/b><\/p><\/td><\/tr>\n<\/table><p>\nThe Guarantors commitments would thus represent <b>75.0%<\/b> of the initial amount of the Offering.<\/p><p>\nUnder the Backstop Agreement as implemented through these Subscription and Underwriting Commitments, each Guarantor shall in any event be entitled to the payment of a fee equal to 8% of the aggregate amount of its subscription and underwriting commitments, i.e. a total aggregate amount of EUR 2,400,000 for the Guarantors, payable by way of set-off of a certain and payable receivable in New Shares on the settlement-delivery date of the Offer and, as the case may be, of the Reserved Offer, representing 480,000 New Shares (the \u201c<b>Commission<\/b>\u201d). The amount of the Commission shall be due to the Guarantors regardless of the structure of the transaction (whether or not the guarantee is exercised).<\/p><p>\nIn the event that the number of New Shares subscribed for in the context of the Public Offering and the Global Placement by the public and qualified investors does not allow the Guarantors to be allocated the full amount of their respective commitments, the number of New Shares required to enable each of them to subscribe for the entirety of its underwriting commitment shall be issued in the context of the Reserved Offer, for a maximum amount of EUR 10,000,000, allocated in the proportions set out in the table above.<\/p><p>\nThe Company further specifies that, in the context of a potential conflict of interest identified in relation to Lion Point Capital, represented on the Board of Directors by Mr Didric Cederholm, the latter did not take part in the deliberations or in the vote of the Board of Directors relating to the Backstop Agreement or the relevant share capital increase.<\/p><p>\nThe related-party transactions procedure was implemented in accordance with the applicable regulations with respect to the prior approval of the Backstop Agreement by the Company\u2019s Board of Directors.<\/p><p>\nThe Company further states that it has complied with its disclosure and communication obligations and considers that it has not failed to disclose to the market any inside information in connection with the transaction, in accordance with applicable regulations.<\/p><p>\nThe agreements between Lion Point Capital, the Guarantors and the Company do not provide for any change in the Company\u2019s governance.<\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<b>MEDIAN TECHNOLOGIES<\/b><br\/><b>Emmanuelle Leygues<\/b><br\/>VP, Corporate Marketing &amp; Financial Communications\n<br\/>+33 6 10 93 58 88\n<br\/><a  href=\"mailto:emmanuelle.leygues@mediantechnologies.com\" rel=\"nofollow\" shape=\"rect\">emmanuelle.leygues@mediantechnologies.com<\/a><\/p><p>\n<b>Press \u2013 MAARC<\/b><br\/><b>Bruno Arabian<\/b><br\/>+33 6 87 88 47 26\n<br\/><a  href=\"mailto:bruno.arabian@maarc.fr\" rel=\"nofollow\" shape=\"rect\">bruno.arabian@maarc.fr<\/a><\/p><p>\n<b>Investors - SEITOSEI ACTIFIN<\/b><br\/><b>Ghislaine Gasparetto<\/b><br\/>+33 6 85 36 76 81\n<br\/><a  href=\"mailto:ghislaine.gasparetto@seitosei-actifin.com\" rel=\"nofollow\" shape=\"rect\">ghislaine.gasparetto@seitosei-actifin.com<\/a><\/p><br\/> <a href=\"http:\/\/www.businesswire.com\/news\/home\/20260526575567\/en\/Median-Technologies-Launches-a-Capital-Increase-of-%E2%82%AC40-million-with-Potential-Upsize-to-%E2%82%AC50-million-to-Support-the-Deployment-of-eyonis%C2%AE-LCS-in-the-U.S.-and-Europe-and-Advance-New-Clinical-Indications-for-Its-Proprietary-eyonis%C2%AE...\/?feedref=Zd8jjkgYuzBwDixoAdXmJgT1albrG1Eq4mAeVP39212bri8lIe-zl5tWvCOnRHW3evRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxY5fjCLYi_If30KxIsYuhwbuLAuCkn8FS6sh-I3dfDZEg==\"> Read full story here <\/a>","protected":false},"excerpt":{"rendered":"<p>Share capital increase without shareholders\u2019 preferential subscription rights, to be carried out by way of an issue of ordinary shares in the framework of a public offering, for an amount of approximately 40 million euros.<\/p>\n<p>A share capital increase w&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-11447","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/11447","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11447"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/11447\/revisions"}],"predecessor-version":[{"id":11448,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/11447\/revisions\/11448"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11447"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11447"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11447"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}